Holen Sie sich die Stockscreener-App
1.59
3.05%
-0.05
Vorhandelsmarkt:
1.65
0.06
+3.77%
Schlusskurs vom Vortag:
$1.64
Offen:
$1.64
24-Stunden-Volumen:
807.06K
Relative Volume:
0.41
Marktkapitalisierung:
$482.23M
Einnahmen:
$6.23M
Nettoeinkommen (Verlust:
$-95.90M
KGV:
-4.0769
EPS:
-0.39
Netto-Cashflow:
$-68.47M
1W Leistung:
-12.15%
1M Leistung:
-9.14%
6M Leistung:
+67.99%
1J Leistung:
+9.66%
1-Tages-Spanne:
$1.57
$1.64
1-Wochen-Bereich:
$1.545
$1.87
52-Wochen-Spanne:
$0.6513
$2.17
Precigen Inc Stock (PGEN) Company Profile
Firmenname
Precigen Inc
Sektor
Branche
Telefon
301-556-9900
Adresse
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD
Vergleichen Sie PGEN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PGEN
Precigen Inc
|
1.59 | 482.23M | 6.23M | -95.90M | -68.47M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Precigen Inc Stock (PGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-03-22 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-05-23 | Eingeleitet | JP Morgan | Neutral |
| 2022-11-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-02-25 | Eingeleitet | Stifel | Buy |
| 2021-02-22 | Eingeleitet | Wells Fargo | Overweight |
| 2021-02-18 | Eingeleitet | B. Riley Securities | Buy |
| 2020-05-08 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Precigen Inc Aktie (PGEN) Neueste Nachrichten
Is Precigen (PGEN) The Hot Biotech Stock Under $5? - Insider Monkey
Precigen, Inc. (NASDAQ:PGEN) Q4 2024 Earnings Call Transcript - Insider Monkey
Cantor Fitzgerald raises Precigen stock target to $5 By Investing.com - Investing.com Australia
10 Hot Biotech Stocks Under $5 - Insider Monkey
Precigen’s Earnings Call: Positive Outlook Amid Challenges - TipRanks
Precigen Inc (PGEN) Q4 2024 Earnings Report Preview: What To Exp - GuruFocus.com
Precigen’s SWOT analysis: biotech firm’s stock poised for potential launch By Investing.com - Investing.com South Africa
Analysts Are Bullish on Precigen Stock (PGEN) Amid Positive Pipeline Developments - Markets Insider
ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Precigen, Inc. f/k/a Intrexon Corporation Investors of Important Deadline in Securities Class Action First Filed by the Firm – PGEN, XON - Business Wire
Stifel maintains Precigen stock Buy rating with $7 target By Investing.com - Investing.com South Africa
Precigen’s SWOT analysis: biotech firm’s stock poised for potential launch - Investing.com India
Expert Outlook: Precigen Through The Eyes Of 4 Analysts - Nasdaq
Cantor Fitzgerald raises Precigen stock target to $5 - Investing.com
Stifel maintains Precigen stock Buy rating with $7 target - Investing.com
H.C. Wainwright reiterates buy on Precigen stock, maintains $6 target By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates buy on Precigen stock, maintains $6 target - Investing.com
Earnings call transcript: Precigen Q4 2024 sees net loss, stock rises By Investing.com - Investing.com South Africa
Precigen Inc (PGEN) Q4 2024 Earnings Call Highlights: Navigating Challenges and Seizing ... - Yahoo Finance
Precigen Inc (PGEN) Q4 2024 Earnings Call Highlights: Navigating Challenges and Seizing Opportunities - GuruFocus.com
Precigen earnings beat by $0.02, revenue fell short of estimates - Investing.com Canada
Precigen Reports Progress and Financial Results for 2024 - TipRanks
Precigen Reports Full Year 2024 Financial Results and Business Updates - The Malaysian Reserve
Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates - MSN
Earnings call transcript: Precigen Q4 2024 sees net loss, stock rises - Investing.com Canada
Precigen Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Precigen Inc Reports Q4 Net Loss of $(0.47) Per Share, Revenue o - GuruFocus.com
PRECIGEN, INC. SEC 10-K Report - TradingView
How Do Things Look For Precigen Inc (NASDAQ: PGEN) In The Short-Term? - Stocks Register
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Precigen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm - Business Wire
Precigen, Inc. (NASDAQ:PGEN) Receives $7.00 Consensus Price Target from Brokerages - Defense World
Analysts Set Precigen, Inc. (NASDAQ:PGEN) Price Target at $7.00 - MarketBeat
Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th - Quantisnow
Precigen Gene Therapy Pioneer Reveals 2024 Performance: Key Financial Results Coming March 19 - StockTitan
Exploring High Growth Tech Stocks In The US Market - Simply Wall St
Precigen, Inc. (NASDAQ:PGEN) Stock Holdings Increased by Rhumbline Advisers - Defense World
Precigen (PGEN) Projected to Post Earnings on Tuesday - Defense World
Is Precigen Inc’s (NASDAQ:PGEN) Stock On The Decline? - Stocks Register
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
Why Precigen, Inc. (PGEN) is Skyrocketing So Far in 2025 - Insider Monkey
Precigen (NASDAQ:PGEN) Shares Gap UpWhat's Next? - MarketBeat
Precigen (NASDAQ:PGEN) Shares Up 7.7%Time to Buy? - MarketBeat
Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement (NASDAQ:PGEN) - Seeking Alpha
Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement (PGEN) - Seeking Alpha
FDA advances Precigen’s gene therapy for respiratory disease By Investing.com - Investing.com Australia
FDA Accepts for Review Precigen RRP Gene Therapy Candidate - Genetic Engineering & Biotechnology News
Stifel maintains Precigen stock Buy rating, $7 target post-FDA update - Investing.com Australia
FDA Accepts BLA for Precigen’s Recurrent Respiratory Papillomatosis Gene Therapy PRGN-2012 With Priority Review - CGTLive™
Decades in, this Germantown biopharma is on the cusp of bringing its first product to market - The Business Journals
Finanzdaten der Precigen Inc-Aktie (PGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.91%
0.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):